

Attorney's Docket No: L0461/7097

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant** 

Heidecker et al.

Serial No.

09/692,401

Filed

October 19, 2000 October 19, 2000
MAGE-A12 ANTIGENIC PEPTIDES AND USES THEREOFTECH CENTER 1600/2900

For

Examiner

Art Unit

1644

## CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 27<sup>th</sup> day of September, 2001.

Commissioner for Patents Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

[X]Amendment

[X]Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

If the any fee is required, the fee may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

John R. Van Amsterdam, Reg No. 40,212

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, MA 02210

Telephone (617) 720-3500

Docket No. L0461/7097 Dated: September 27, 2001 X10/03/01

Attorney's Docket No.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant** 

Heidecker et al.

Serial No.

09/692,401

Filed

October 19, 2000

For

MAGE-A12 ANTIGENIC PEPTIDES AND USES THEREOF

Examiner

M. DiBring

Art Unit

1644

OCT 0 5 2001

TECH CENTER 1600/2900

## CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 27th day of September, 2001.

Commissioner for Patents Washington, D.C. 20231

**AMENDMENT** 

Sir:

Please amend the application as follows.

## In the Claims:

Please amend the claims as follows. Applicants have included herewith pages showing the markups of the claims with insertions and deletions indicated by underlining and bracketing, respectively.

1.(amended) An isolated MAGE-A12HLA class I-binding peptide comprising the amino acid sequence of SEQ ID NO:6, or a functional variant thereof which binds a HLA class I molecule comprising one amino acid addition, substitutions or deletion.